Gillibrand, Scott Applaud Senate Help Committee Passage Of Bipartisan CLEAR LABELS Act

Gillibrand, Scott Applaud Senate Help Committee Passage Of Bipartisan CLEAR LABELS Act

Jul 23, 2026

Today, U.S. Senator Kirsten Gillibrand (D-NY), ranking member of the Senate Aging Committee, and Aging Committee Chairman Rick Scott (R-FL) announced committee passage of their Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. This bill would add country of origin labeling requirements to the U.S.' prescription drug supply chain.

"Americans deserve to know where their prescription drugs are manufactured so they can make informed health care decisions," said Senator Gillibrand. "The CLEAR LABELS Act would make this information readily accessible to patients, pharmacists, purchasers, and providers while strengthening accountability throughout the supply chain. I am grateful for Chairman Scott's partnership on this crucial piece of legislation, and I am thrilled that it just passed out of the Senate HELP Committee. I will not stop fighting until this bill is passed by the full Congress and signed into law."

"Today's passage of the CLEAR LABELS Act in the U.S. Senate HELP Committee is a massive win for consumer safety and transparency, and America's national security," said Senator Scott. "Through more than a half dozen hearings and our investigative report, the U.S. Senate Special Committee on Aging has exposed the dangers posed by foreign generic drugs, especially those made in Communist China and India. Our work has shown the urgent need for reforms to ensure Americans know where their drugs are made so they can be confident that their medications are safe for themselves and their families. I want to thank Ranking Member Gillibrand for leading this important legislation with me, and HELP Chairman Bill Cassidy and Ranking Member Bernie Sanders for their partnership to secure committee passage of this good bill. We cannot be depended on an evil foreign adversary for medications that our seniors, our military, and millions of Americans rely on. I look forward to passing this bill in the Senate and House of Representatives, so President Trump can sign it into law as soon as possible."

The CLEAR LABELS Act passed out of the Senate Health, Education, Labor, and Pensions (HELP) Committee with a bipartisan vote of 21-1. It now heads to the full Senate for final passage from the chamber.

Many prescription drugs, and their active pharmaceutical ingredients (APIs), are manufactured overseas, particularly in China and India. However, current federal labeling requirements do not require public disclosure of where those ingredients or finished products are made. As a result, patients, pharmacists, and healthcare providers lack visibility into the origins of their medications. Transparency is the first step in determining vulnerabilities in the drug supply chain to prevent threats to the availability of safe and effective medications for American patients.

The CLEAR LABELS Act would require prescription drug labels to disclose the original manufacturers of prescription drugs and APIs to ensure patients, providers, and regulators have clear, upfront information about where the drugs they rely on day after day are made.

The full text of the CLEAR LABELS Act can be found here.

###